Prospective Pilot Study Identifying Clinically Relevant Biological Targets for Medical Therapy

Conditions

• Craniopharyngioma, Child

Eligibility Criteria

Sex

ALL

Age

30 Days - 21 Years

Healthy Volunteers

Not accepted

Interventions

• Tumor and Blood Specimens — PROCEDURE
  If available, specimen will be sampled from within the tumor, and not include portions of the tumor capsule. If the tumor includes a cyst, fluid from the cyst will be sampled if available. For each tumor specimen, a companion sample of blood that would otherwise be disposed of through usual clinical practice in the operating room will also be collected.

Study Details

New data suggests that the current treatment for pediatric adamantinomatous craniopharyngioma (CPA) may not be as effective as it could be.

Key Dates

Start date

Mar 12, 2019

Status verified

Mar 2026

Primary completion

Feb 2, 2030

Completion

Dec 31, 2030

Study Design

Enrollment

250 participants (estimated)

Arms

• Arm: Pediatrics with Tumors
  Pediatrics who have a tumor specimen that is suspected to be craniopharyngioma, but is deemed superfluous to the clinical care of the patient (e.g. pathological diagnosis).

Primary Outcome Measure

Identification of Potential Therapeutic Targets [ Time Frame: Beginning of study to end of study, up to 1 year. ]

Locations (1)

Find similar trials in Aurora, CO

Related Studies

• Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults
  PHASE2 · Recruiting · Sabine Mueller, MD, PhD · Birmingham, Alabama